THERAPY DOSSIER · th-c90b9d2f6aea

Margatoxin (MgTX)

Biologic · Margatoxin, a scorpion-venom peptide Kv1.3 channel blocker.

Evidence & regulatory context

Mechanism: Margatoxin, a scorpion-venom peptide Kv1.3 channel blocker.
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32025214 ↗2020Reported benefit

Blockage of Kv1.3 regulates macrophage migration in acute liver injury by targeting delta-catenin through RhoA signaling.

MouseEndotoxin/LPSC57BL/6MaleIntraperitoneal100 nM margatoxin (in vivo); 5-10 nM in RAW264.7 cell assays

Model: Acute liver injury induced by intraperitoneal lipopolysaccharide (3 ug/kg) plus D-galactosamine (200 mg/kg)

Margatoxin treatment attenuated acute liver injury, with reduced hepatic macrophage infiltration, less histological damage and lower serum ALT, AST and TNF-alpha. Transcriptomic analysis identified downregulation of delta-catenin, and delta-catenin overexpression or knockdown correspondingly increa…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…